Food Allergy Market Summary

• According to DelveInsight’s analysis, the Food Allergy Market Size was found to be ~USD 2,700 million in the leading markets (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
• The leading Food Allergy Companies include DBV Technologies, Roche, Novartis, Aravax, ARS Pharmaceuticals, ALK-Abelló, Alfresa Pharma, Stallergenes Greer, Aquestive Therapeutics, Novartis, Aravax, Siolta Therapeutics, RAPT Therapeutics, and others.

Food Allergy Market and Epidemiology Insights

• The Food Allergen Labeling and Consumer Protection Act (FALCPA) require that food packaging identify any of the “Top 9” allergens—milk, eggs, peanuts, tree nuts, soy, wheat, fin fish, shellfish, and sesame—when present in a product. However, manufacturers are not obligated to disclose the use of highly refined oils derived from peanuts, tree nuts, or soy.
• The high incidence of anaphylaxis and serious allergic reactions (SAR) among patients in the high-risk cohort underscores a significant unmet medical need. This is particularly concerning given the lack of approved preventive treatments for anaphylaxis in food allergy patients classified as high-risk.
• The current standard of care and effective management of food allergy is avoidance of the allergen and the use of an Adrenaline Auto-injector (AAI) in the event of an allergic reaction.
• Antihistamines, corticosteroids, and bronchodilators may also be used, but it is essential to realize these medications do not treat anaphylaxis; rather, they are adjunctive therapies for anaphylaxis management.
• Epinephrine is the first-line medication for the treatment of anaphylaxis. Intramuscular (IM) or intravenous (IV) epinephrine should be administered, although the IM route is preferred, with injection placement in the lateral thigh. Intravenous administration is done in the inpatient setting with appropriate monitoring. Epinephrine via intranasal administration, and sublingual are expected to change the future epinephrine prescribing habits, as these options solves the needle hesitancy, convenience and bulkiness issue.
• Although avoidance is the mainstay of treatment, new strategies are being tested to prevent food allergies. Immunotherapy clinical trials have been promising to date using incremental ingestion of small amounts of food allergens over time with Oral Immunotherapy (OIT). OIT potential is limited by unresolved challenges, such as refining patient selection by allergy phenotype, determining the ideal age to start treatment, and extending efficacy beyond peanut allergies to other allergens.
• Currently, peanut allergen powder (PALFORZIA), omalizumab (XOLAIR), and epinephrine nasal spray (NEFFY) are the only approved medications offering important treatment options for patients with food allergies and healthcare providers. PALFORZIA is specifically approved for peanut allergy, while XOLAIR is approved for multiple allergens.
• The evolving food allergy treatment landscape features clinical trials led by DBV Technologies (Viaskin [DBV712] Peanut Patch), Novartis (Remibrutinib), Aravax (PVX108), ALK-Abello (Sublingual Immunotherapy-Tablet), InnoUp Farma (INP20), Allergy Therapeutics (VLP Peanut), Intrommune Therapeutics (INT301), Regeneron Pharmaceuticals (Linvoseltamab + Dupilumab), RAPT Therapeutics (RPT904), and others.
• GSK is also strengthened its position in the food allergy market by acquiring RAPT Therapeutics to gain ozureprubart.
• Novartis' oral BTK inhibitor that showed a good response rate in Phase II peanut allergy trials; however, despite the promise of rapid action and convenient oral dosing, experts remain cautious about its long-term use in children due to potential immune system development concerns.

Request for Unlocking the Sample Page of "Food Allergy Treatment Market"

Food Allergy Market Size and Forecast

Key Factors Driving the Growth of the Food Allergy Market

• Rising Food Allergy Prevalence

The increasing prevalence of food allergy, particularly among children and adolescents, is driven by changing dietary patterns, environmental factors, and improved diagnostic awareness. In the 7MM, the diagnosed prevalent cases are expected to rise steadily through 2036, increasing the overall treatment demand.

• Growing Opportunities in Novel Immunotherapies

Advances in oral, epicutaneous, and biologic therapies are expanding treatment options beyond allergen avoidance and emergency management. Emerging therapies aimed at desensitization and long-term tolerance induction are creating significant opportunities for innovation.

• Evolving Competitive Landscape

The food allergy pipeline is rapidly expanding, with therapies such as Viaskin, remibrutinib, SLIT tablet, VLP Peanut, and others advancing across different stages of development, reflecting increasing industry focus on improving efficacy, convenience, and patient outcomes.

DelveInsight's ‘Food Allergy Market Insights, Epidemiology and Market Forecast – 2036’ report delivers an in-depth understanding of the food allergy, historical and forecasted epidemiology, as well as the food allergy market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Food Allergy Treatment Market Report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates, food allergy patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022–2036) across global regions. The report highlights key unmet medical needs in food allergy and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Food Allergy Understanding and Treatment Algorithm

Food Allergy Overview and Diagnosis

Food allergy is an immune response to food proteins and can be either IgE-mediated or non-IgE-mediated. IgE-mediated food allergy is a major global health concern, commonly triggered by foods such as milk, eggs, peanuts, tree nuts, fish, shellfish, wheat, and soy. Reactions can affect multiple body systems, ranging from mild symptoms like hives and vomiting to severe, life-threatening anaphylaxis. Early introduction has shown protective benefits mainly for peanut and egg allergy, while evidence for other allergenic foods remains limited.

Patients with food allergies, especially those with asthma, a history of severe reactions, or allergies to peanuts, nuts, seeds, or seafood, should carry self-injectable epinephrine and have a written emergency plan. Diagnosis involves in vivo methods such as skin-prick tests and allergy blood tests, which measure allergen-specific IgE levels. Intradermal testing is not recommended due to its high risk of false positives and severe reactions, while Atopy Patch Tests (APTs) may be helpful in specific cases like eosinophilic esophagitis. The oral food challenge remains the gold standard for confirming food allergies. In vitro testing, including sIgE blood tests like RadioAllergoSorbent Test (RAST) and Fluorescence Enzyme ImmunoAssay (FEIA), is useful when skin tests are not feasible. The advanced AllerScan test improves accuracy by detecting IgE reactivity to specific allergenic epitopes for precise food and environmental allergy profiling.

Further details are provided in the report.

Current Food Allergy Treatment Landscape

Current treatment of food allergy mainly focuses on strict avoidance of allergenic foods and prompt management of accidental reactions. Epinephrine remains the first-line treatment for severe allergic reactions and anaphylaxis. Supportive medications such as antihistamines may help relieve mild symptoms but do not prevent severe reactions. Recently, oral immunotherapy and biologic therapies have emerged as options to reduce sensitivity and improve tolerance in selected patients. Regular monitoring and patient education are essential for effective long-term management.

Further details related to country-based variations are provided in the report.

Food Allergy Unmet Needs

The section “unmet needs of Food Allergy” outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

• Addressing Psychological Burden and Transition of Care
• Challenge of Managing Multiple Food Allergies
• Limitations of Current Approved Therapies for Food Allergy
• Need for Improved Diagnostic Strategies, and others…..

Note: Comprehensive unmet needs insights in food allergy and their strategic implications are provided in the full report.

Food Allergy Epidemiology

Key Findings from Food Allergy Epidemiological Analysis and Forecast

• The total number of prevalent cases of food allergy in the 7MM ranges from approximately 45 million in 2025.
• Among the gender-specific contribution, male had the highest occurrence of cases from ~55% in 2025 in the US.
• In EU4 and the UK, maximum cases of food allergy were in Spain with ~25%, whereas the minimum number of cases were in France in 2025.
• The total number of physician diagnosed prevalent cases of food allergy in the US were ~11 million in 2025.
• In 2025, within the 7MM, on the basis of severity in adults, the number of food allergy cases was more in severe; ~8.5 million then mild to moderate. These numbers are expected to rise by 2036.
• In 2025, shellfish allergy was the most common type of food allergy in the US with the highest number of cases; ~25%.

Food Allergy Epidemiology Segmentation in the 7MM

• Total Food Allergy Prevalent Cases
• Food Allergy Physician-Diagnosed Prevalent Cases
• Food-Challenge-defined Food Allergy Cases
• Food Allergy Gender-specific Diagnosed Prevalent Cases
• Food Allergy Allergen-specific Diagnosed Prevalent Cases
• Food Allergy Severity-specific Diagnosed Prevalent Cases
• Total Food Allergy Treated Cases

Food Allergy Market Recent Breakthroughs and Developments

• In May 2026, as per the company’s presentation DBV Technologies reached an understanding with the US FDA based on written replies to its Type D IND meeting request. The FDA concurred with DBV’s proposal that safety exposure data from the VITESSE Phase III study of the Viaskin Peanut Patch in children aged 4–7 years would be sufficient to support BLA filing for this age group, thereby accelerating the anticipated timeline for BLA submission to the first half of 2026. The BLA submission for the 1–3-year-old indication is expected in the second half of 2026, subject to the successful completion of the COMFORT Toddlers Study.
• In February 2026, DBV Technologies announced that the company shared additional positive data from the successful Phase III VITESSE clinical trial as an oral presentation today at the American Academy of Allergy, Asthma, and Immunology (AAAAI) 2026 Annual Meeting.
• In February 2026, in the company’s presentation, Anaphylm is an investigational sublingual epinephrine film being developed by Aquestive Therapeutics for the emergency treatment of severe allergic reactions, including anaphylaxis; the company received a CRL from the FDA on January 30, 2026, and plans to resubmit the NDA in Q3 2026.
• In February 2026, in the Q4 2025 presentation, the Novartis presentation indicates remibrutinib reported positive Phase II results, with Phase III initiation expected in H2 2026.
• In January 2026, GSK announced that it entered into a definitive agreement to acquire RAPT Therapeutics for ozureprubart.

Food Allergy Drug Analysis & Competitive Landscape

The food allergy drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I/II–II clinical trials. It covers mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, strategic partnerships upcoming Key catalyst for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the food allergy treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the food allergy therapeutics market.

Approved Therapies for Food Allergy

• Peanut Allergen Powder-dnfp (PALFORZIA): Stallergenes Greer

Peanut allergen powder-dnfp (PALFORZIA) is an oral immunotherapy treatment indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanuts for patients. Because of the risk of anaphylaxis, peanut allergen powder-dnfp is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the PALFORZIA REMS. The REMS is in place for peanut allergen powder-dnfp to mitigate the risk of anaphylaxis associated with peanut allergen powder-dnfp, which includes elements to assure safe use, which includes elements to assure safe use. Peanut allergen powder-dnfp is the first and only US FDA-approved OIT for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanuts for patient’s ages 1–17 years.

Stallergenes Greer will discontinue the commercialization of peanut allergen powder-dnfp as of July 31, 2026. The decision is based on strategic and operational considerations at Stallergenes.

In December 2025, Stallergenes notified the EMA of its decision to stop marketing the product in the EU by March 31, 2027. No new patients should be started on peanut allergen powder-dnfp after 31 March 2026. There are no authorised therapeutic alternatives available in the EU

• Omalizumab (XOLAIR): Roche and Novartis

Omalizumab (XOLAIR) is an FDA-approved medicine to reduce allergic reactions in people with one or more food allergies. Omalizumab is given as an injection under the skin, either by a healthcare provider or at home through self-injection (after initiating treatment in a healthcare setting). Omalizumab (XOLAIR) still carries its FDA Boxed Warning for life-threatening anaphylaxis. While the specific REMS (Risk Evaluation and Mitigation Strategy) was lifted by the FDA in December 2011, the mandatory boxed warning remains a permanent requirement due to the potential for delayed allergic reactions.

The FDA approved omalizumab-igec (OMLYCLO) in March 2025 as the first and only biosimilar interchangeable with omalizumab for IgE-mediated food allergies, potentially increasing treatment accessibility and fostering greater market competition and launched anticipated in H2 2026.

Food Allergy Pipeline Analysis

Viaskin (DBV712 and DBV135) Peanut and Milk Patch: DBV Technologies

Viaskin Peanut, developed by DBV Technologies, is an investigational EPIT designed to deliver small quantities of peanut protein through a wearable skin patch to promote gradual immune desensitization while potentially minimizing systemic allergic reactions associated with oral immunotherapy. The therapy is currently being evaluated in Phase III clinical development for the treatment of peanut allergy in young children and is positioned as a convenient, non-invasive, and patient-friendly alternative approach for long-term allergy management.

DBV Technologies’s Viaskin Milk is an investigational EPIT patch designed to deliver small quantities of milk allergen through the skin to promote gradual immune desensitization in patients with cow’s milk allergy. The therapy aims to provide a non-invasive and potentially safer alternative to oral immunotherapy by reducing the risk of systemic allergic reactions while supporting long-term allergy management. This is currently evaluated in a Phase I/II clinical trial.

Remibrutinib (RHAPSIDO/LOU064): Novartis

Remibrutinib (RHAPSIDO), developed by Novartis, is an investigational oral Bruton’s Tyrosine Kinase (BTK) inhibitor designed to suppress mast cell and basophil activation involved in allergic and inflammatory responses. The therapy is being evaluated across multiple immune-mediated diseases, including food allergy, and has demonstrated rapid symptom control, sustained efficacy, and a favorable safety profile. In the US, Novartis Pharmaceuticals Corporation and Genentech, a member of the Roche Group, work together to develop and co-promote XOLAIR. The drug is currently being evaluated in Phase II clinical trials for Food allergy.

Food Allergy Market Outlook

Currently, approved treatment options include immunotherapy, such as oral dose escalation of allergenic food proteins or a branded peanut allergen powder, and biologic therapy like Omalizumab (XOLAIR), which is administered via subcutaneous injection. While desensitization-based food allergen-specific immunotherapies involving other modes of administration are in development, such as SLIT or EPIT, these are not yet approved or commercially available.

The food allergy treatment market is undergoing a significant transformation, driven by rising prevalence, increasing awareness, and advances in therapeutic approaches. Historically, management has relied heavily on strict allergen avoidance and emergency interventions, particularly the use of epinephrine autoinjectors such as EpiPen, Auvi-Q, and Adrenaclick. These interventions, though life-saving, do not address the underlying immune response and are primarily designed for acute management rather than long-term treatment.

Currently, the only approved medications providing significant treatment options for food allergy patients and healthcare providers are peanut allergen powder (PALFORZIA), Omalizumab (XOLAIR), and epinephrine nasal spray (NEFFY). Peanut allergen powder is specifically approved to treat peanut allergy, whereas XOLAIR is approved for use with multiple allergens.

In addition to approved therapies, several key players are actively involved in the development of food allergy treatments, indicating strong momentum in the field. These include DBV Technologies (Viaskin), Novartis (Remibrutinib), Aravax (PVX108), ALK-Abelló (SLIT-tablet), Allergy Therapeutics (VLP Peanut), and RAPT Therapeutics (RPT904). This growing pipeline underscores the expanding therapeutic landscape and increasing efforts to address the unmet needs in food allergy management. The food allergy treatment market is growing steadily, driven by the increasing use of biologics, improved diagnosis, and rising awareness. The US accounts for the largest market size of chronic food allergy, in comparison toEU4 and the UK (Germany, France, Italy, the UK, and Spain) and Japan.

Overall, the launch of first-in-class therapies, improved genetic testing, and rising disease awareness are expected to drive steady growth in the 7MM food allergy market from 2022–2036, with strong commercial implications for both marketed products and emerging pipelines.

• Among the 7MM, the US accounted for the largest market size of food allergy. i.e., USD ~2,300 million in 2025.
• In 2036, among all the therapies for food allergy, the highest revenue is estimated to be generated by Viaskin followed by epinephrine, in the US.
• The entry of late-stage candidates such as viaskin is expected to intensify competition in the food allergy treatment landscape during the latter forecast period.

Food Allergy Companies

• DBV Technologies
• Roche
• Novartis
• Aravax
• ARS Pharmaceuticals
• ALK-Abelló
• Alfresa Pharma
• Stallergenes Greer
• Aquestive Therapeutics
• Novartis
• Aravax
• Siolta Therapeutics
• RAPT Therapeutics, and others

Food Allergy Drug Class/Insights into Leading Emerging and Marketed Therapies (2022–2036 Forecast)

• Bruton's Tyrosine Kinase (BTK) inhibitors

BTK inhibitors target a crucial enzyme involved in the activation of immune cells like B cells, mast cells, and basophils that drive allergic reactions. By blocking BTK, these inhibitors prevent the signaling pathways that lead to the release of histamine and other inflammatory mediators responsible for allergy symptoms. This reduces the severity of immune responses to food allergens, helping to prevent or minimize reactions such as anaphylaxis. BTK inhibitors are being studied as a promising new treatment to improve safety and control in managing food allergies by directly modulating the underlying immune mechanisms.

Anti-IgE Therapy

Anti-IgE therapy works by targeting and neutralizing Immunoglobulin E (IgE), the antibody responsible for triggering allergic reactions. By binding to free IgE in the bloodstream, anti-IgE treatments prevent IgE from attaching to immune cells like mast cells and basophils. This stops these cells from releasing histamine and other chemicals that cause allergy symptoms, reducing the severity and frequency of allergic reactions.

Desensitization

Desensitization refers to the process of gradually exposing the immune system to increasing amounts of an allergen to shift the response from allergic to protective. Over time, this exposure retrains the immune system to tolerate the allergen without triggering a harmful reaction. Desensitization raises the threshold for allergic responses, lowering the risk of severe reactions such as anaphylaxis and improving patients’ quality of life.

Food Allergy Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026–2036). The analysis covers the food allergy drug’s uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

The uptake of therapies in the US food allergy market is expected to vary based on patient age, clinical profile, route of administration, and level of clinical validation. Omalizumab (XOLAIR) is anticipated to achieve the fastest uptake, supported by its established efficacy, broad eligibility across food allergens, and strong commercial presence in the US market.

Detailed insights of emerging therapies' drug uptake is included in the report

Food Allergy Market Access and Reimbursement of Approved Therapies

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

The US

Reimbursement is a crucial factor that affects the drug’s access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

Food Allergy Therapies Price Scenario & Trends

Pricing and analogue assessment of food allergy therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

Pricing of food allergy Approved Drugs

The current list price of omalizumab (XOLAIR) is approximately USD 30,000–60,000 annually, but most people will not pay this amount. The amount you pay for omalizumab depends on a variety of factors, including your insurance coverage, diagnosed condition and HCP prescribed dose and frequency. So the estimated price of omalizumab to be around USD 45,000.

Industry Experts and Physician Views for Epidermal Growth Factor Receptor Food Allergy

To keep up with food allergy market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the food allergy emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in food allergy, including MD, Ph.D, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight’s analysts connected with 15+ KOLs to gather insights at country level. Centers such as the Ohio State University, Johns Hopkins University, Stanford University, King’s College London, and University of Southern California, etc. were contacted. Their opinion helps understand and validate current and emerging food allergy therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in food allergy.

Food Allergy Report Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis. In the SWOT analysis of food allergy strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial’s primary and secondary outcome measures are evaluated, whereas the therapies’ safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed.

In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Food Allergy Market Report

• The report covers a segment of key events, an executive summary, a descriptive overview of food allergy, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the food allergy market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM food allergy market.

Food Allergy Market Report Insights

• Food Allergy Patient Population Forecast
• Food Allergy Therapeutics Market Size
• Food Allergy Pipeline Analysis
• Food Allergy Market Size and Trends
• Food Allergy Market Opportunity (Current and forecasted)

Food Allergy Market Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-enabled Market Research Report
• 11-year forecast
• Food Allergy Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (by geography)
• Food Allergy Treatment Addressable Market (TAM)
• Food Allergy Competitive Landscape
• Food Allergy Major Companies Insights
• Food Allergy Price Trends and Analogue Assessment
• Food Allergy Therapies Drug Adoption/Uptake
• Food Allergy Therapies Peak Patient Share Analysis

Food Allergy Market Report Assessment

• Food Allergy Current Treatment Practices
• Food Allergy Unmet Needs
• Food Allergy Clinical Development Analysis
• Food Allergy Emerging Drugs Product Profiles
• Food Allergy Market Attractiveness
• Food Allergy Qualitative Analysis (SWOT and conjoint analysis)

Key Questions Answered in the Food Allergy Treatment Market Report

Food Allergy Therapeutics Market Insights

• What was the food allergy market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of food allergy?
• What impact will patent expiry have on the food allergy therapy market?
• When is the discontinuation of PALFORZIA expected to have a noticeable impact on the food allergy market, and how might it influence treatment dynamics and patient access over the forecast period?
• What are the disease risks, burdens, and unmet needs of food allergy? What will be the growth opportunities across the 7MM concerning the patient population with food allergy?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of food allergy? What are the current guidelines for treating food allergy in the US, Europe, and Japan?

Reasons to Buy the Food Allergy Therapeutics Market Report

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the food allergy market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs’ perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Stay updated with us for Recent Articles

• Revolutionizing the Food Allergy Treatment: The Impact of Xolair’s Approval
• Most Promising Therapies in the Food Allergy Treatment Market
• Egg Allergy Market: Second most common food allergy but no approved therapy
• Food Allergy Market Infographics
• New DelveInsight Blogs